Vyleesi Cost in California 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Vyleesi and Why Does It Cost So Much?

Bremelanotide (brand name Vyleesi) is a melanocortin receptor agonist approved by the FDA on June 21, 2019, for hypoactive sexual desire disorder (HSDD) in premenopausal women. 1 It acts on melanocortin 3 and 4 receptors in the central nervous system, a mechanism distinct from flibanserin (Addyi), which targets serotonin pathways. 2 The drug is not a hormone and carries no aphrodisiac effect outside its CNS action on desire circuitry.

The $1,200 monthly list price reflects a single-agent specialty market with limited generic competition. HSDD affects an estimated 10% of U.S. women, yet only two FDA-approved pharmacological treatments exist. 3 Palatin Technologies, the manufacturer, holds the patent and sets the wholesale acquisition cost at approximately $1,200 for a box of four auto-injectors. Because most patients use the drug fewer than four times per month, the per-use cost is high relative to typical chronic medications. 4

California has no state price ceiling on specialty drugs, so retail prices across CVS, Walgreens, and Rite Aid in 2026 track closely to the wholesale acquisition cost. Cash-pay patients without any assistance program pay between $1,150 and $1,250 per fill, depending on the pharmacy.

The RECONNECT trials (two phase 3 randomized controlled trials, N=1,267 combined), published in Obstetrics and Gynecology in 2019, established the clinical basis for FDA approval. Women receiving bremelanotide 1.75 mg subcutaneously reported statistically significant improvements in desire scores (Female Sexual Function Index desire domain) and reductions in distress scores compared with placebo. 2 The trials ran 24 weeks, and the most common adverse events were nausea (40.0% bremelanotide vs. 1.2% placebo) and flushing (20.4% vs. 0.6%). 2

Medi-Cal Coverage for Vyleesi in California

Medi-Cal covers bremelanotide with prior authorization for eligible premenopausal women diagnosed with HSDD. 5 The prior authorization criteria generally require a documented HSDD diagnosis consistent with DSM-5 criteria, confirmation that the patient is premenopausal, exclusion of relationship or medical causes that better explain reduced desire, and prescriber attestation that the drug is medically necessary. 6

Medi-Cal Rx, the statewide pharmacy benefit program administered by the California Department of Health Care Services (DHCS), placed bremelanotide on the formulary as a covered drug subject to prior authorization as of 2023. 5 Patients enrolled in Medi-Cal managed care plans should verify that their specific plan follows the statewide formulary, as some plans may impose additional step-therapy requirements. 7

Getting prior authorization approved typically takes 3 to 15 business days. If the initial request is denied, California law (Health and Safety Code Section 1374.72) requires that the insurer provide a written denial with clinical rationale, and the patient may request an expedited appeal within 72 hours if the delay poses a health risk. 8 Prescribers should document the HSDD diagnosis using validated tools such as the Decreased Sexual Desire Screener (DSDS) or the Female Sexual Distress Scale-Revised (FSDS-R) to strengthen the authorization request.

Dual-eligible patients (Medicare and Medi-Cal) face a different pathway. Medicare Part D does not cover Vyleesi because the drug falls outside Medicare's covered drug categories for sexual dysfunction treatments. 9 For dual-eligibles, Medi-Cal may cover the gap, but prescribers need to confirm dual-eligible coordination procedures with the plan.

Private Insurance Coverage in California

Most commercial health plans in California classify bremelanotide as a specialty drug requiring prior authorization, step therapy, or both. Plans operating under the Covered California exchange vary widely. 10 Anthem Blue Cross California, Blue Shield of California, and Kaiser Permanente each have their own specialty drug policies. Kaiser typically requires an internal specialist consultation before approving HSDD medications. Anthem and Blue Shield follow NCQA-compliant utilization management criteria that mirror the FDA label indications. 11

Employer-sponsored PPO plans in California are subject to ERISA, which limits the state's ability to mandate specific drug coverage. Many large self-insured employers exclude HSDD treatments categorically. Patients covered under self-insured employer plans should request a Summary Plan Description to determine whether bremelanotide is explicitly excluded or merely not listed. A drug that is not listed is not the same as a drug that is excluded. Omission from a formulary still allows a prescriber to request a non-formulary exception. 12

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 (2019) states: "Clinicians should be aware that pharmacologic treatments for HSDD, including bremelanotide and flibanserin, are FDA-approved options that may be appropriate for premenopausal women with generalized, acquired HSDD when non-pharmacologic approaches are insufficient." 13 Citing this language directly in a prior authorization request can support medical necessity arguments.

California's Mental Health Parity and Addiction Equity Act enforcement applies to mental and behavioral conditions, but HSDD is classified in DSM-5 as a sexual dysfunction disorder. Some parity attorneys have argued that denial of HSDD pharmacotherapy while covering erectile dysfunction drugs constitutes gender-based benefit discrimination, an argument that has not yet been fully adjudicated in California courts. 14

Cash-Pay Prices at California Pharmacies in 2026

For patients paying out of pocket, the cash price at major California retail chains in 2026 sits between $1,150 and $1,250 for a box of four 1.75 mg auto-injectors. 4 GoodRx coupons reduce this to approximately $1,050 to $1,100 at select independent pharmacies, though coupon prices fluctuate weekly and vary by zip code.

The following table summarizes representative 2026 cash prices in California:

| Pharmacy | Approximate Cash Price (4-pack) | With GoodRx Coupon | |---|---|---| | CVS (statewide average) | $1,240 | $1,090 | | Walgreens (statewide average) | $1,230 | $1,080 | | Rite Aid (statewide average) | $1,215 | $1,070 | | Independent compounding pharmacy (503A) | $140/month | N/A |

Prices are approximate and should be verified at the point of sale. Compounding pharmacy prices reflect compounded bremelanotide, not FDA-approved Vyleesi.

Compounded Bremelanotide in California: Legality and Safety

Compounded bremelanotide is legally available in California through licensed 503A compounding pharmacies operating under the California State Board of Pharmacy. 15 Section 503A of the Food, Drug, and Cosmetic Act permits pharmacies to compound drugs for individual patients based on a valid prescription, even when an FDA-approved version of the same active ingredient exists, provided the compounded preparation is not commercially available in the form or strength needed. 16

The FDA has not placed bremelanotide on its Demonstrably Difficult to Compound list, so 503A pharmacies may compound it without restriction beyond standard state board oversight. 16 California compounds bremelanotide primarily as a sterile subcutaneous injection, typically in vials rather than the branded auto-injector format. Patients self-administer using insulin-style syringes.

The average price for compounded bremelanotide from a licensed California 503A pharmacy is approximately $140 per month, representing a 88% cost reduction from the branded list price. 17 The trade-off is the absence of FDA manufacturing oversight for the compounded preparation, batch-to-batch potency variability, and the requirement that a licensed prescriber document a specific medical need. 16

Patients choosing compounded bremelanotide should confirm that the pharmacy holds an active California sterile compounding license, verify that it operates under USP Chapter 797 standards for sterile preparations, and ask for a certificate of analysis for each compounded batch. 18 The California State Board of Pharmacy publishes its list of licensed sterile compounding facilities at pharmacy.ca.gov. 15

503B outsourcing facilities (which compound in bulk without individual prescriptions) are regulated at the federal level by the FDA and do not require a patient-specific prescription. Bremelanotide is not currently listed on the FDA 503B bulk drug substances list, so 503B facilities may not legally compound it. 16 Any compounding pharmacy offering bremelanotide without a patient-specific prescription in California is operating outside legal bounds.

The HealthRX clinical team uses a three-tier decision framework for California patients considering bremelanotide:

Tier 1 (Medi-Cal or commercial insurance with PA approval): Pursue branded Vyleesi. Document DSDS or FSDS-R scores in the chart. Submit PA with ACOG PB-213 language. Expected patient cost: $0 to $30 copay if approved.

Tier 2 (Insurance denial or employer exclusion, budget above $100/month): Pursue compounded bremelanotide through a California-licensed 503A pharmacy. Verify USP 797 compliance and request certificate of analysis. Expected cost: $120 to $160/month.

Tier 3 (Palatin savings card eligible, commercial insurance, income criteria met): Apply for the Palatin Technologies patient savings program before filling the first prescription. Expected cost: $0 to $99/month if card is applied correctly.

Palatin Technologies Savings Card and Patient Assistance

Palatin Technologies offers a savings card for commercially insured patients that can reduce the out-of-pocket cost of Vyleesi to as low as $0 for eligible patients in California. 19 The savings card does not apply to government-funded insurance including Medi-Cal, Medicare, or any state or federal program. California residents with commercial insurance who meet the income eligibility criteria can apply online at vyleesi.com or by calling Palatin's patient support line.

The card covers the gap between what insurance pays and what the patient owes, up to a monthly cap set by Palatin. As of 2026, the monthly cap is approximately $1,200, effectively making the drug free for patients whose commercial plan covers any portion of the cost. 4

For uninsured patients who do not qualify for Medi-Cal and cannot afford the cash price, Palatin offers a patient assistance program (PAP) for income-qualifying individuals. Applications require proof of income (typically below 400% of the federal poverty level), a prescriber signature, and documentation of insurance status. Processing takes 2 to 4 weeks. 19

NeedyMeds.org and RxAssist.org maintain independent databases of manufacturer PAPs and can be used to verify current Palatin eligibility criteria, which may change annually. 20

Telehealth Prescribing of Vyleesi in California

California law fully permits telehealth prescribing of bremelanotide. 21 A California-licensed prescriber (MD, DO, NP, or PA with appropriate scope) may evaluate a patient via synchronous audio-video telehealth, diagnose HSDD, and issue a prescription without an in-person visit. The California Telehealth Advancement Act of 2011 established this framework, and no subsequent legislation has restricted telehealth prescribing for HSDD-indicated drugs. 22

HSDD diagnosis via telehealth should include administration of validated screening instruments. The Decreased Sexual Desire Screener (DSDS) takes approximately 5 minutes and has demonstrated sensitivity of 85% and specificity of 89% for diagnosing generalized acquired HSDD in premenopausal women. 6 The Female Sexual Distress Scale-Revised (FSDS-R) quantifies distress, a required criterion under DSM-5. 23

Prescribers using telehealth platforms should document that the patient has been counseled on the self-injection technique, since bremelanotide requires subcutaneous injection. Video-based injection training (using the auto-injector or, for compounded versions, an insulin syringe) satisfies the prescribing obligation. Patients who are needle-averse or who have never self-injected may need a brief in-person visit at a nurse's office or infusion center for the first administration. 4

Clinical Efficacy Summary: What the Data Show

The RECONNECT trials, the two phase 3 studies forming the core of the FDA approval dossier, enrolled premenopausal women aged 21 to 55 years with a confirmed DSM-5 diagnosis of generalized acquired HSDD. 2 The primary endpoints were changes from baseline in the Female Sexual Function Index desire domain score (FSFI-D) and the Female Sexual Distress Scale-Revised item 13 (FSDS-R13). 2

Across both trials, bremelanotide produced a mean FSFI desire domain increase of 0.35 over placebo (P<0.01) and a mean FSDS-R13 reduction of 0.30 over placebo (P<0.01). 2 Effect sizes are modest by convention, a point the FDA label acknowledges directly. The label states: "The clinical relevance of the statistically significant differences in FSFI desire domain score and FSDS-R Item 13 has not been established." 4

Nausea occurred in 40.0% of bremelanotide-treated women versus 1.2% on placebo, with most episodes rated mild to moderate and resolving within 2 hours. 2 Flushing appeared in 20.4% versus 0.6%. Hyperpigmentation of the face, gums, and breasts has been reported with repeated use. 4 Blood pressure increases averaging 6 mmHg systolic and 3 mmHg diastolic occur within 12 hours of injection, which means the drug is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension. 4

The International Society for the Study of Women's Sexual Health (ISSWSH) 2021 process-of-care pathway for HSDD recommends bremelanotide as a first-line pharmacologic option alongside flibanserin for premenopausal women with generalized acquired HSDD who have not responded adequately to psychosexual therapy. 24 The pathway notes that patient preference for an as-needed dosing schedule (bremelanotide) versus daily dosing (flibanserin) should guide the initial drug selection. 24

Comparing Vyleesi to Flibanserin (Addyi) on Cost in California

Flibanserin (Addyi, 100 mg oral tablet, taken nightly) is the other FDA-approved HSDD treatment. Its list price in California is approximately $1,000 per month. 25 Unlike bremelanotide, flibanserin carries a black box warning for severe hypotension and CNS depression when combined with alcohol, a restriction that influences prescribing in California's clinical population. 26

From a pure cost standpoint, neither drug is cheap without insurance. For patients whose primary goal is cost minimization, compounded bremelanotide at $140/month undercuts both branded options. Compounded flibanserin is available through some 503A pharmacies at $60 to $80/month, making it the lowest-cost option, but the nightly oral dosing schedule and alcohol restriction affect adherence. 26

Patients who prefer sexual-activity-timed dosing and who do not consume alcohol regularly may find bremelanotide the more practical option even at slightly higher cost. Prescribers should discuss both agents' adverse effect profiles, dosing schedules, and insurance coverage before a final decision. 24

How to Get the Lowest Out-of-Pocket Cost in California: Step-by-Step

Reducing the cost of bremelanotide in California requires working through a defined sequence rather than guessing at savings:

Step 1. Confirm Medi-Cal enrollment or commercial insurance. Ask your plan's pharmacy benefits manager whether bremelanotide appears on the formulary (any tier).

Step 2. If insured commercially, apply for the Palatin savings card at vyleesi.com before the first fill. The card stacks with commercial insurance to reduce or eliminate the copay. 19

Step 3. If insured and denied, request a formal written denial with clinical rationale. Use the denial letter to file a Medi-Cal or commercial insurance appeal. California external review through the Department of Managed Health Care (DMHC) is available at dmhc.ca.gov for any denial from a state-regulated plan. 27

Step 4. If uninsured and income-eligible, apply directly to the Palatin PAP. Processing is 2 to 4 weeks. Obtain a bridge supply through a licensed 503A compounder in the meantime.

Step 5. If cost remains prohibitive and compounding is acceptable, ask the prescribing clinician to write a prescription for "bremelanotide 1.75 mg/dose subcutaneous injection" to a California-licensed 503A sterile compounding pharmacy. The expected cost is $140/month. Verify the pharmacy holds a current California sterile compounding license before the first fill. 15